ALNY实时信号 | 通过Getagraph.com最大化利润

出售 178 min ago

@ $152.10

发出时间: 3 May 2024 @ 21:30

回报率: 0.28%

上一信号: May 2 - 21:33

上一信号: 购买

回报率: 1.95 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 00:27):

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference...

Stats
今日成交量	174 341
平均成交量	834 624
市值	19.29B
EPS	$0 ( 2024-05-02 )
下一个收益日期	( $-1.180 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-43.33
ATR14	$3.31 (2.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-20	Fitzgerald Kevin Joseph	Sell	0	Common Stock
2024-03-20	Fitzgerald Kevin Joseph	Buy	0	Common Stock
2021-02-11	Fitzgerald Kevin Joseph	Sell	9 000	Performance Stock Option 2017 (right to buy)
2024-03-20	Fitzgerald Kevin Joseph	Sell	16 250	Stock Option (right to buy)
2024-03-20	Fitzgerald Kevin Joseph	Sell	6 667	Stock Option (right to buy)

INSIDER POWER
-6.10
Last 99 transactions
Buy: 237 064 \| Sell: 275 392

音量相关性

長: -0.82 (strong negative)

短: -0.76 (moderate negative)

Signal:(34) Neutral

Alnylam Pharmaceuticals 相关性

10 最正相关
KRNY	0.958
INDB	0.956
MRBK	0.955
CYXT	0.951
RVSB	0.95
HAFC	0.949
BMRC	0.948
DCOM	0.947
MNSB	0.945
CBNK	0.945

10 最负相关
IIN	-0.943
THRX	-0.942
MYNA	-0.939
ALXN	-0.936
BRAC	-0.934
ICVX	-0.933
KRTX	-0.932
TA	-0.931
FLXS	-0.928
ECHO	-0.927

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Alnylam Pharmaceuticals 相关性 - 货币/商品

-0.30
( neutral )

-0.60
( weak negative )

0.34
( neutral )

-0.16
( neutral )

-0.25
( neutral )

0.67
( moderate )

Alnylam Pharmaceuticals 财务报表

Annual	2023
营收:	$1.83B
毛利润:	$1.52B (83.02 %)
EPS:	$-3.52

FY	2023
营收:	$1.83B
毛利润:	$1.52B (83.02 %)
EPS:	$-3.52

FY	2022
营收:	$1.04B
毛利润:	$868.60M (83.73 %)
EPS:	$-9.30

FY	2021
营收:	$844.29M
毛利润:	$704.14M (83.40 %)
EPS:	$-7.20

Financial Reports:

No articles found.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.